These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 20188527

  • 1. Potential of doripenem for the treatment of infections with multidrug-resistant Pseudomonas spp.
    Naesens R, Jansens H, Goossens H, Ieven M, Vlieghe E.
    Int J Antimicrob Agents; 2010 May; 35(5):514-5. PubMed ID: 20188527
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.
    Nicolau DP, Carmeli Y, Crank CW, Goff DA, Graber CJ, Lima AL, Goldstein EJ.
    Int J Antimicrob Agents; 2012 Jan; 39(1):11-5. PubMed ID: 22047702
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Current therapies for pseudomonas aeruginosa.
    Giamarellou H, Kanellakopoulou K.
    Crit Care Clin; 2008 Apr; 24(2):261-78, viii. PubMed ID: 18361945
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.
    Chen Y, Garber E, Zhao Q, Ge Y, Wikler MA, Kaniga K, Saiman L.
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2510-1. PubMed ID: 15917558
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A novel combination regimen for the treatment of refractory bacteremia due to multidrug-resistant Pseudomonas aeruginosa in a liver transplant recipient.
    Sun HY, Shields RK, Cacciarelli TV, Muder RR, Singh N.
    Transpl Infect Dis; 2010 Dec; 12(6):555-60. PubMed ID: 20626709
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
    Castanheira M, Jones RN, Livermore DM.
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):426-33. PubMed ID: 19249180
    [Abstract] [Full Text] [Related]

  • 14. [Characterization of a Chrysemonas luteola strain isolated from a healthy carrier and investigation of pathogenicity, virulence and antibiotic resistance factors through in vitro and in vivo studies].
    Israil A, Balotescu C, Alexandru I.
    Bacteriol Virusol Parazitol Epidemiol; 2004 Apr; 49(1-2):43-7. PubMed ID: 16752751
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Use of Etest to assess synergy of antibiotic combinations against clinical isolates of Pseudomonas spp.
    Fodor E, Hajdú E, Nagy E.
    Int J Antimicrob Agents; 2005 Feb; 25(2):183-4. PubMed ID: 15664494
    [No Abstract] [Full Text] [Related]

  • 19. Gastrointestinal selective capacity of doripenem, meropenem, and imipenem for carbapenem-resistant gram-negative bacilli in treated patients with pneumonia.
    Apisarnthanarak A, Kiratisin P, Apisarnthanarak P, Mundy LM.
    Infect Control Hosp Epidemiol; 2011 Apr; 32(4):410-1. PubMed ID: 21460501
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.